Search

Vivani Medical

Geschlossen

1.47 7.3

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.46

Max

1.5

Schlüsselkennzahlen

By Trading Economics

Einkommen

-147K

-6.8M

Angestellte

42

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+157.05% upside

Dividenden

By Acuity

Nächstes Ergebnis

12. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

25M

102M

Vorheriger Eröffnungskurs

-5.83

Vorheriger Schlusskurs

1.47

Vivani Medical Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

5. Sept. 2026, 23:51 UTC

Core PPI Release on September 10 Expected to Show 0.3% Increase Amid Strong Employment Data and Speculation of Fed Rate Hikes Due to Inflation Concerns.

5. Sept. 2026, 23:41 UTC

U.S. Producer Price Inflation Expected to Rise 0.3% in August Amid Strong Job Growth and Heightened Interest Rate Hike Speculation

5. Sept. 2026, 23:31 UTC

Euro Area's Deposit Facility Rate Expected to Rise to 0.025% Amid ECB Tightening and Investor Caution Ahead of September Release

5. Sept. 2026, 23:01 UTC

Australia's Consumer Confidence Set for Release Amid Mixed Economic Signals and Global Uncertainties

5. Sept. 2026, 22:51 UTC

Mexico's Inflation Rate Release on September 9, 2026, Sparks Market Concerns Amid Strong U.S. Jobs Data and Potential Interest Rate Adjustments.

5. Sept. 2026, 22:51 UTC

Mexico's August 2026 Inflation Rate Release Expected to Influence Monetary Policy and Investor Confidence Amid Easing Trends.

5. Sept. 2026, 22:51 UTC

Australia's Westpac Consumer Confidence Index set for release on September 8, amid positive market trends and strong U.S. job growth influencing economic outlook.

5. Sept. 2026, 22:41 UTC

U.S. MBA 30-Year Mortgage Rate Set to Rise Amid Strong Job Growth and Inflation Concerns, Influencing Fed Interest Rate Expectations

5. Sept. 2026, 22:31 UTC

Brazil's Central Bank readout on interest rates set for September 8, 2026, amid global economic influences and heightened speculation in financial markets.

5. Sept. 2026, 22:21 UTC

Japan's Q2 2026 GDP Growth Forecast at 1.1% Amid Concerns Over Sharp Decline in Household Spending

5. Sept. 2026, 22:21 UTC

Japan's Q2 2026 GDP Growth Rate Release Expected at 0.4% Amid Mixed Economic Signals and Volatile Markets

5. Sept. 2026, 22:11 UTC

Turkey's TCMB Expected to Maintain 37% Interest Rate Amid Inflation Concerns and Global Market Influences Ahead of September Decision.

5. Sept. 2026, 22:11 UTC

UK Housing Market Sentiment Remains Negative as RICS House Price Balance Forecasts Slight Improvement Amid Broader Economic Concerns

5. Sept. 2026, 21:51 UTC

South Korea's Unemployment Rate Release on September 8, 2026, Expected Amid Global Job Growth Optimism Following Strong U.S. Data

5. Sept. 2026, 21:31 UTC

Cautious Market Sentiment Ahead of BRC Retail Sales Monitor YoY Release, Forecasting 1.2% Growth Amid Mixed Economic Signals

5. Sept. 2026, 21:21 UTC

Spain's Consumer Confidence Index set for release on September 8, with analysts hopeful for improvement amid geopolitical tensions and inflation concerns.

5. Sept. 2026, 21:21 UTC

South Africa's Q2 2026 GDP Growth Rate Release on September 8 Sparks Cautious Optimism Amid Global Economic Trends.

5. Sept. 2026, 21:21 UTC

South Africa's Q2 2026 GDP Growth Rate Release on September 8 Sparks Cautious Optimism Amid Global Economic Recovery Signals.

5. Sept. 2026, 20:41 UTC

Japan's Current Account Surplus Forecasted at JPY 2,870 Billion Amid Cautious Sentiment from Declining Household Spending

5. Sept. 2026, 19:21 UTC

API Crude Oil Stock Change Data Release on September 9, 2026, Anticipated Amid Geopolitical Tensions and Recent Inventory Volatility.

5. Sept. 2026, 19:11 UTC

Italy's Industrial Production MoM data for July 2026 set to release on September 10, with a forecasted increase of only 0.3% amid declining trends and mixed signals from Europe.

5. Sept. 2026, 19:01 UTC

Correlated Moves

Cardano is rising during Saturday's session, supported by Ethereum's performance. The asset is trading above its 20-day moving average, reflecting strong momentum.

5. Sept. 2026, 18:31 UTC

Swiss Consumer Confidence Index Expected to Remain Low at -32.0 Amidst Cautious Market Sentiment and Global Economic Concerns

5. Sept. 2026, 18:11 UTC

EUR/SEK is trading roughly flat in after-market hours, showing little change since Friday's close and remaining near the upper end of its one-month range.

5. Sept. 2026, 18:11 UTC

EUR/CAD is trading roughly flat in after-market hours, showing little change from Friday's close and remaining near the lower end of its one-month range.

5. Sept. 2026, 18:11 UTC

Turkey's Industrial Production YoY data release on September 10, 2026, may reflect cautious optimism amid recent fluctuations and mixed market sentiment.

5. Sept. 2026, 17:41 UTC

U.S. Monthly Budget Statement on September 11, 2026, expected to reveal rising deficits amid cautious fiscal sentiment and potential Fed interest rate decisions.

5. Sept. 2026, 17:41 UTC

France's Industrial Production Expected to Rise 0.3% Amid Cautious Economic Sentiment and Construction Sector Decline

5. Sept. 2026, 17:31 UTC

UK's Non-EU Goods Trade Balance Report Set for Release on September 11, 2026 Amidst Stable Market Sentiment.

5. Sept. 2026, 17:31 UTC

UK Monthly GDP Expected to Remain Flat at 0.0% for July Amid Cautious Investor Sentiment and Mixed Economic Signals

Peer-Vergleich

Kursveränderung

Vivani Medical Prognose

Kursziel

By TipRanks

157.05% Vorteil

12-Monats-Prognose

Durchschnitt 3.83 USD  157.05%

Hoch 4 USD

Tief 3.5 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Vivani Medical – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

3 ratings

3

Buy

0

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Gewinn vor Steuern

Verkäufe

Betriebsergebnis

$

Über Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.
help-icon Live chat